ATE228004T1 - Verwendung von relaxin zur stimulierung der angiogenese - Google Patents

Verwendung von relaxin zur stimulierung der angiogenese

Info

Publication number
ATE228004T1
ATE228004T1 AT96928212T AT96928212T ATE228004T1 AT E228004 T1 ATE228004 T1 AT E228004T1 AT 96928212 T AT96928212 T AT 96928212T AT 96928212 T AT96928212 T AT 96928212T AT E228004 T1 ATE228004 T1 AT E228004T1
Authority
AT
Austria
Prior art keywords
relaxin
stimulate angiogenesis
angiogenesis
infections
lack
Prior art date
Application number
AT96928212T
Other languages
English (en)
Inventor
Elaine Unemori
Original Assignee
Connetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connetics Corp filed Critical Connetics Corp
Application granted granted Critical
Publication of ATE228004T1 publication Critical patent/ATE228004T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96928212T 1995-08-15 1996-08-15 Verwendung von relaxin zur stimulierung der angiogenese ATE228004T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US235595P 1995-08-15 1995-08-15
PCT/US1996/013321 WO1997006814A1 (en) 1995-08-15 1996-08-15 Method of promoting angiogenesis

Publications (1)

Publication Number Publication Date
ATE228004T1 true ATE228004T1 (de) 2002-12-15

Family

ID=21700396

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96928212T ATE228004T1 (de) 1995-08-15 1996-08-15 Verwendung von relaxin zur stimulierung der angiogenese

Country Status (9)

Country Link
US (3) US6211147B1 (de)
EP (1) EP0845992B1 (de)
JP (1) JP4568383B2 (de)
AT (1) ATE228004T1 (de)
AU (1) AU6777196A (de)
CA (1) CA2229479C (de)
DE (1) DE69624925T2 (de)
ES (1) ES2187667T3 (de)
WO (1) WO1997006814A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60128540T2 (de) * 2000-02-09 2008-01-31 Bas Medical, Inc., San Mateo Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
ITRM20020119A1 (it) * 2002-03-05 2003-09-05 Geymonat Spa Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
EP1765149B1 (de) * 2004-03-19 2016-09-28 University Of Pittsburgh Verwendung von relaxin zur erhöhung der arteriencompliance
WO2005115435A2 (en) * 2004-04-30 2005-12-08 Bas Medical, Inc. Methods and compositions for control of fetal growth via modulation of relaxin
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
CA2604441A1 (en) * 2005-04-12 2006-10-19 Intradigm Corporation Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
US20060281669A1 (en) * 2005-06-13 2006-12-14 Yue Samuel K Method and compositions for the treatment of diabetes and related complications
US8496446B2 (en) * 2005-08-29 2013-07-30 Carrier Corporation Compressor muffler
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
TWI386202B (zh) * 2008-05-16 2013-02-21 Corthera Inc 治療與急性心臟衰竭相關之呼吸困難的方法
WO2009140661A1 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of preventing premature delivery
US20100041603A1 (en) * 2008-05-16 2010-02-18 Corthera, Inc. Method of Promoting Wound Healing
BRPI0805852A8 (pt) * 2008-09-05 2021-06-29 Univ Rio De Janeiro polímeros ácidos protéicos, processos de produção, uso de polímeros ácidos protéicos, composição farmacêutica e método de tratamento
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
US20110152770A1 (en) 2009-07-30 2011-06-23 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
FI3572091T3 (fi) 2010-08-17 2024-03-01 Ambrx Inc Muokattuja relaksiinipolypeptidejä ja niiden käyttötapoja
WO2013033324A2 (en) * 2011-08-31 2013-03-07 University Of Florida Research Foundation, Inc. Materials and methods for modulating activity of bone marrow derived cells
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9526762B1 (en) * 2013-08-09 2016-12-27 William Marsh Rice University Multidomain peptides for promoting angiogenesis
EP4011919A3 (de) 2015-12-09 2022-10-12 The Scripps Research Institute Relaxin-immunglobulin-fusionsproteine und verfahren zur verwendung

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
WO1989007945A1 (en) 1988-02-26 1989-09-08 Genentech, Inc. Human relaxin formulation
GB8907799D0 (en) * 1989-04-06 1989-05-17 Erba Carlo Spa Heteroaryl-3-oxo-propanenitrile derivatives useful in the treatment of rheumatoid arthritis and other autoimmune diseases
JP2857684B2 (ja) 1989-05-04 1999-02-17 ジェネンテク，インコーポレイテッド ヒトリラキシンの単離のための方法および組成物
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
US5478807A (en) 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
US5952296A (en) 1993-07-27 1999-09-14 Bigazzi; Mario Method of using relaxin as therapeutic or preventing agent
US5811395A (en) * 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
US5911997A (en) 1995-06-07 1999-06-15 Connetics Corporation Relaxin-like factor and methods and uses thereof
US5753623A (en) * 1995-06-07 1998-05-19 Connetics Corporation Method of treatment for depression

Also Published As

Publication number Publication date
EP0845992A1 (de) 1998-06-10
US6211147B1 (en) 2001-04-03
JP4568383B2 (ja) 2010-10-27
CA2229479C (en) 2010-03-30
DE69624925D1 (de) 2003-01-02
US20010018418A1 (en) 2001-08-30
US6780836B2 (en) 2004-08-24
AU6777196A (en) 1997-03-12
DE69624925T2 (de) 2003-09-04
EP0845992A4 (de) 2000-04-19
EP0845992B1 (de) 2002-11-20
US20040192606A1 (en) 2004-09-30
WO1997006814A1 (en) 1997-02-27
CA2229479A1 (en) 1997-02-27
JPH11511174A (ja) 1999-09-28
ES2187667T3 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
ATE228004T1 (de) Verwendung von relaxin zur stimulierung der angiogenese
DE69034018D1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE3855489D1 (de) Behandlung von Hautfalten
DE3687069D1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
ATE233558T1 (de) Verwendung von strontiumsälze zur behandlung von arthrose
ES2038609T3 (es) 4,5-dihidroisoxazol, 3,5 disustituido como inhibidores de transglutaminasa.
ATE113208T1 (de) Verwendung des wirkstoffs azelastin zur bekämpfung von psoriasis-erkrankungen.
DE3869485D1 (de) Behandlung von autophoretisch abgeschiedenen ueberzuegen zur glanzverbesserung.
DE3772513D1 (de) Behandlung von gewebe zur verbesserung seiner anfaerbbarkeit.
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
ATE95694T1 (de) Verwendung von bezafibrat zur behandlung von diabetes.
FI864570A0 (fi) Terapeutiskt anvaendbar foerening.
DE69634905D1 (de) Phosphnatanaloge von Mannose-6-phosphate und deren Verwendung zur Förderung der Heilung von Wunden oder fibrotischen Störungen mit verminderter Narbenbildung
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE143804T1 (de) Zusammensetzung zur behandlung von mastitis und metritis
ATE179594T1 (de) Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
ATE190486T1 (de) Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen
ES2076141T3 (es) 5-aril-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
DE59808165D1 (de) Verwendung von aminothiazolen zur wund- und hautbehandlung
ATE104142T1 (de) Verwendung von probucol zur praevention und behandlung von herzkrankheiten.
ATE216884T1 (de) Verwendung von sulbutiamin zur behandlung von psychomotorischen oder psychointellektuellen beschwerden
IT8719277A0 (it) Capelli. composizione per il trattamento ela stimolazione della crescita dei
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
DE69802828D1 (de) Verwendung von 6,7-substituierter 2-aminotetraline zur behandlung von zytokin-vermittleten entzündungszuständen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0845992

Country of ref document: EP